Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer

Anne Li                                                                                     Feburary 24th, 2018


Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. The results of a multi-institutional, phase 3 clinical trial of apalutamide — led by investigators from Massachusetts General Hospital (MGH) and University of California, San Francisco (UCSF) — are receiving early release publication in the New England Journal of Medicine to coincide with a presentation today at the American Society for Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
See original article at: https://www.sciencedaily.com/releases/2018/02/180208162013.htm

Post a comment